AI Terminal
PROCESSING_QUERY...
Novo Nordisk
Director's Dealing • Feb 6, 2025
3375_rpt_2025-02-06_d33e032b-6610-4ca1-8dc2-8765325e6525.pdf
Director's Dealing
Open in ViewerOpens in native device viewer
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 6 February 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
Telephone: +45 4444 8888
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
|
|---|---|---|
| a) | Name of the Board member/Executive/Associated Person |
Liselotte Sofie Hyveled |
| 2 | Reason for the notification | |
| a) | Position/status | Member of the Board of Directors |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer | |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| 4 | Details of the transaction(s) | |
| a) | Description of the financial instrument, type of instrument, |
Shares |
| Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
| c) | Price(s) and volume(s) | |
| Price(s) Volume(s) |
||
| DKK 0.00 1,407 shares |
||
| d) | Aggregated information • Aggregated volume • Price |
1,407 shares DKK 0.00 |
| e) | Date of the transaction | 2025-02-05 |
| f) | Place of the transaction | Outside a trading venue |
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
|
|---|---|---|
| a) | Name of the Board member/Executive/Associated Person |
Lars Fruergaard Jørgensen |
| 2 | Reason for the notification | |
| a) | Position/status | President and CEO |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer | |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| 4 | Details of the transaction(s) | |
| a) | Description of the financial instrument, type of instrument, |
Shares |
| Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
| c) | Price(s) and volume(s) | |
| Price(s) Volume(s) |
||
| DKK 0.00 98,702 shares |
||
| d) | Aggregated information | |
| • Aggregated volume |
98,702 shares | |
| • Price |
DKK 0.00 | |
| e) | Date of the transaction | 2025-02-05 |
| f) | Place of the transaction | Outside a trading venue |
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
|
|---|---|---|
| a) | Name of the Board member/Executive/Associated Person |
Lars Fruergaard Jørgensen |
| 2 | Reason for the notification | |
| a) | Position/status | President and CEO |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer | |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| 4 | Details of the transaction(s) | |
| a) | Description of the financial instrument, type of instrument, |
Shares |
| Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Sale of shares |
| c) | Price(s) and volume(s) | |
| Price(s) Volume(s) |
||
| 618.10 DKK 32 shares |
||
| d) | Aggregated information | |
| • Aggregated volume • Price |
32 shares 19,779 DKK |
|
| e) | Date of the transaction | 2025-02-05 |
| f) | Place of the transaction | AQUIS EXCHANGE EUROPE NON DISPLAY ORDER BOOK (NDOB) |
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
|
|---|---|---|
| a) | Name of the Board member/Executive/Associated Person |
Lars Fruergaard Jørgensen |
| 2 | Reason for the notification | |
| a) | Position/status | President and CEO |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer | |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| 4 | Details of the transaction(s) | |
| a) | Description of the financial instrument, type of instrument, |
Shares |
| Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Sale of shares |
| c) | Price(s) and volume(s) | Price(s) Volume(s) 619.48 DKK 1,104 shares |
| d) e) |
Aggregated information • Aggregated volume • Price Date of the transaction |
1,104 shares 683,905 DKK 2025-02-05 |
| f) | Place of the transaction | AQUIS EXCHANGE EUROPE |
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
|
|---|---|---|
| a) | Name of the Board member/Executive/Associated Person |
Lars Fruergaard Jørgensen |
| 2 | Reason for the notification | |
| a) | Position/status | President and CEO |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer | |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| 4 | Details of the transaction(s) | |
| a) | Description of the financial instrument, type of instrument, |
Shares |
| Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Sale of shares |
| c) | Price(s) and volume(s) | |
| Price(s) Volume(s) |
||
| 617.56 DKK 978 shares |
||
| d) | Aggregated information | |
| • Aggregated volume • Price |
978 shares | |
| 603,976 DKK | ||
| e) | Date of the transaction | 2025-02-05 |
| f) | Place of the transaction | CBOE EUROPE - DXE PERIODIC (NL) |
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
|
|---|---|---|
| a) | Name of the Board member/Executive/Associated Person |
Lars Fruergaard Jørgensen |
| 2 | Reason for the notification | |
| a) | Position/status | President and CEO |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer | |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| 4 | Details of the transaction(s) | |
| a) | Description of the financial instrument, type of instrument, |
Shares |
| Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Sale of shares |
| c) | Price(s) and volume(s) | |
| Price(s) Volume(s) |
||
| 621.01 DKK 42 shares |
||
| d) | Aggregated information | |
| • Aggregated volume • Price |
42 shares 26,083 DKK |
|
| e) | Date of the transaction | 2025-02-05 |
| f) | Place of the transaction | CBOE EUROPE - DXE DARK ORDER BOOK (NL) |
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
|
|---|---|---|
| a) | Name of the Board member/Executive/Associated Person |
Lars Fruergaard Jørgensen |
| 2 | Reason for the notification | |
| a) | Position/status | President and CEO |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer | |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| 4 | Details of the transaction(s) | |
| a) | Description of the financial instrument, type of instrument, |
Shares |
| Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Sale of shares |
| c) | Price(s) and volume(s) | |
| Price(s) Volume(s) |
||
| 618.17 DKK 8,331 shares |
||
| d) | Aggregated information | |
| • Aggregated volume • |
8,331 shares | |
| Price | 5,149,984 DKK | |
| e) | Date of the transaction | 2025-02-05 |
| f) | Place of the transaction | CBOE EUROPE - DXE ORDER BOOKS (NL) |
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
|
|---|---|---|
| a) | Name of the Board member/Executive/Associated Person |
Lars Fruergaard Jørgensen |
| 2 | Reason for the notification | |
| a) | Position/status | President and CEO |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer | |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| 4 | Details of the transaction(s) | |
| a) | Description of the financial instrument, type of instrument, |
Shares |
| Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Sale of shares |
| c) | Price(s) and volume(s) | |
| Price(s) Volume(s) |
||
| 618.14 DKK 1,577 shares |
||
| d) | Aggregated information | |
| • Aggregated volume • Price |
1,577 shares | |
| 974,805 DKK | ||
| e) | Date of the transaction | 2025-02-05 |
| f) | Place of the transaction | TURQUOISE EUROPE |
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
|
|---|---|---|
| a) | Name of the Board member/Executive/Associated Person |
Lars Fruergaard Jørgensen |
| 2 | Reason for the notification | |
| a) | Position/status | President and CEO |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer | |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| 4 | Details of the transaction(s) | |
| a) | Description of the financial instrument, type of instrument, |
Shares |
| Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Sale of shares |
| c) | Price(s) and volume(s) | Price(s) Volume(s) 618.88 DKK 22,936 shares |
| d) e) f) |
Aggregated information • Aggregated volume • Price Date of the transaction Place of the transaction |
22,936 shares 14,194,575 DKK 2025-02-05 NASDAQ COPENHAGEN A/S |
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
|
|---|---|---|
| a) | Name of the Board member/Executive/Associated Person |
Maziar Mike Doustdar |
| 2 | Reason for the notification | |
| a) | Position/status | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer | |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| 4 | Details of the transaction(s) | |
| a) | Description of the financial instrument, type of instrument, |
Shares |
| Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
| c) | Price(s) and volume(s) | |
| Price(s) Volume(s) |
||
| DKK 0.00 36,956 shares |
||
| d) | Aggregated information • Aggregated volume • Price |
36,956 shares DKK 0.00 |
| e) | Date of the transaction | 2025-02-05 |
| f) | Place of the transaction | Outside a trading venue |
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
|
|---|---|---|
| a) | Name of the Board member/Executive/Associated Person |
Maziar Mike Doustdar |
| 2 | Reason for the notification | |
| a) | Position/status | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer | |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| 4 | Details of the transaction(s) | |
| a) | Description of the financial instrument, type of instrument, |
Shares |
| Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Sale of shares |
| c) | Price(s) and volume(s) | |
| Price(s) Volume(s) |
||
| DKK 614.55 1,852 shares |
||
| d) | Aggregated information | |
| • Aggregated volume • |
1,852 shares | |
| Price | DKK 1,138,154 | |
| e) | Date of the transaction | 2025-02-05 |
| f) | Place of the transaction | Nasdaq Copenhagen |
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
|
|---|---|---|
| a) | Name of the Board member/Executive/Associated Person |
Ludovic Helfgott |
| 2 | Reason for the notification | |
| a) | Position/status | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer | |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| 4 | Details of the transaction(s) | |
| a) | Description of the financial instrument, type of instrument, |
Shares |
| Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
| c) | Price(s) and volume(s) | |
| Price(s) Volume(s) |
||
| DKK 0.00 27,765 shares |
||
| d) | Aggregated information • Aggregated volume • Price |
27,765 shares DKK 0.00 |
| e) | Date of the transaction | 2025-02-05 |
| f) | Place of the transaction | Outside a trading venue |
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
|
|---|---|---|
| a) | Name of the Board member/Executive/Associated Person |
Ludovic Helfgott |
| 2 | Reason for the notification | |
| a) | Position/status | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer | |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| 4 | Details of the transaction(s) | |
| a) | Description of the financial instrument, type of instrument, |
Shares |
| Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Sale of shares |
| c) | Price(s) and volume(s) | |
| Price(s) Volume(s) |
||
| DKK 614.55 8,990 shares |
||
| d) | Aggregated information | |
| • Aggregated volume • Price |
8,990 shares | |
| DKK 5,524,840 | ||
| e) | Date of the transaction | 2025-02-05 |
| f) | Place of the transaction | Nasdaq Copenhagen |
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
|
|---|---|---|
| a) | Name of the Board member/Executive/Associated Person |
Ludovic Helfgott |
| 2 | Reason for the notification | |
| a) | Position/status | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer | |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| 4 | Details of the transaction(s) | |
| a) | Description of the financial instrument, type of instrument, |
Shares |
| Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Sale of shares |
| c) | Price(s) and volume(s) | |
| Price(s) Volume(s) |
||
| DKK 617.00 12,000 shares |
||
| d) | Aggregated information | |
| • Aggregated volume • Price |
12,000 shares | |
| DKK 7,404,000 | ||
| e) | Date of the transaction | 2025-02-06 |
| f) | Place of the transaction | Nasdaq Copenhagen |
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
|
|---|---|---|
| a) | Name of the Board member/Executive/Associated Person |
Karsten Munk Knudsen |
| 2 | Reason for the notification | |
| a) | Position/status | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer | |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| 4 | Details of the transaction(s) | |
| a) | Description of the financial instrument, type of instrument, |
Shares |
| Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
| c) | Price(s) and volume(s) | |
| Price(s) Volume(s) |
||
| DKK 0.00 30,728 shares |
||
| d) | Aggregated information • Aggregated volume • Price |
30,728 shares DKK 0.00 |
| e) | Date of the transaction | 2025-02-05 |
| f) | Place of the transaction | Outside a trading venue |
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
|
|---|---|---|
| a) | Name of the Board member/Executive/Associated Person |
Martin Holst Lange |
| 2 | Reason for the notification | |
| a) | Position/status | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer | |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| 4 | Details of the transaction(s) | |
| a) | Description of the financial instrument, type of instrument, |
Shares |
| Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
| c) | Price(s) and volume(s) | Price(s) Volume(s) DKK 0.00 30,728 shares |
| d) e) |
Aggregated information • Aggregated volume • Price Date of the transaction |
30,728 shares DKK 0.00 2025-02-05 |
| f) | Place of the transaction | Outside a trading venue |
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
|
|---|---|---|
| a) | Name of the Board member/Executive/Associated Person |
Tania Sabroe |
| 2 | Reason for the notification | |
| a) | Position/status | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer | |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| 4 | Details of the transaction(s) | |
| a) | Description of the financial instrument, type of instrument, |
Shares |
| Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
| c) | Price(s) and volume(s) | |
| Price(s) Volume(s) |
||
| DKK 0.00 10,561 shares |
||
| d) | Aggregated information • Aggregated volume • Price |
10,561 shares DKK 0.00 |
| e) | Date of the transaction | 2025-02-05 |
| f) | Place of the transaction | Outside a trading venue |
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
|
|---|---|---|
| a) | Name of the Board member/Executive/Associated Person |
Marcus Schindler |
| 2 | Reason for the notification | |
| a) | Position/status | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer | |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| 4 | Details of the transaction(s) | |
| a) | Description of the financial instrument, type of instrument, |
Shares |
| Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
| c) | Price(s) and volume(s) | Price(s) Volume(s) DKK 0.00 30,728 shares |
| d) e) |
Aggregated information • Aggregated volume • Price Date of the transaction |
30,728 shares DKK 0.00 2025-02-05 |
| f) | Place of the transaction | Outside a trading venue |
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
||
|---|---|---|---|
| a) | Name of the Board member/Executive/Associated Person |
Camilla Sylvest | |
| 2 | Reason for the notification | ||
| a) | Position/status | Executive Vice President | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, |
Shares | |
| Identification code | Novo Nordisk B DK0062498333 | ||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
|
| c) | Price(s) and volume(s) | ||
| Price(s) Volume(s) |
|||
| DKK 0.00 30,728 shares |
|||
| d) | Aggregated information • Aggregated volume • Price |
30,728 shares DKK 0.00 |
|
| e) | Date of the transaction | 2025-02-05 | |
| f) | Place of the transaction | Outside a trading venue |
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
|
|---|---|---|
| a) | Name of the Board member/Executive/Associated Person |
Camilla Sylvest |
| 2 | Reason for the notification | |
| a) | Position/status | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer | |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| 4 | Details of the transaction(s) | |
| a) | Description of the financial instrument, type of instrument, |
Shares |
| Identification code | Novo Nordisk B DK0062498333 | |
| b) | Nature of the transaction | Sale of shares |
| c) | Price(s) and volume(s) | |
| Price(s) Volume(s) |
||
| DKK 615.00 15,364 shares |
||
| d) | Aggregated information | |
| • Aggregated volume • Price |
15.364 shares | |
| e) | Date of the transaction | DKK 9,448,860 2025-02-05 |
| f) | Place of the transaction | Nasdaq Copenhagen |
| 1 | Details of the person discharging managerial responsibilities/person closely associated |
||
|---|---|---|---|
| a) | Name of the Board member/Executive/Associated Person |
Henrik Ehlers Wulff | |
| 2 | Reason for the notification | ||
| a) | Position/status | Executive Vice President | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, |
Shares | |
| Identification code | Novo Nordisk B DK0062498333 | ||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term Incentive programme) |
|
| c) | Price(s) and volume(s) | ||
| Price(s) Volume(s) |
|||
| DKK 0.00 32,448 shares |
|||
| d) | Aggregated information • Aggregated volume • Price |
32,448 shares DKK 0.00 |
|
| e) | Date of the transaction | 2025-02-05 | |
| f) | Place of the transaction | Outside a trading venue |
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
Media:
Ambre James-Brown +45 3079 9289 [email protected] Liz Skrbkova (US) +1 609 917 0632 [email protected]
Investors: Jacob Martin Wiborg Rode +45 3075 5956 [email protected]
Sina Meyer +45 3079 6656 [email protected]
Max Ung +45 3077 6414 [email protected] David Heiberg Landsted +45 3077 6915 [email protected]
Ida Schaap Melvold +45 3077 5649 [email protected]
Frederik Taylor Pitter +1 609 613 0568 [email protected]
Novo Nordisk A/S Investor Relations
Novo Alle 1 2880 Bagsværd Denmark
Telephone: +45 4444 8888
More from Novo Nordisk
Regulatory Filings
2025
Dec 22
Regulatory Filings
2025
Dec 22
Foreign Filer Report
2025
Nov 25
Regulatory Filings
2025
Nov 25
Earnings Release
2025
Nov 25
Foreign Filer Report
2025
Nov 24
Regulatory Filings
2025
Nov 24
Regulatory Filings
2025
Nov 24
Foreign Filer Report
2025
Nov 17
Director's Dealing
2025
Nov 17